Hims, Keeps and other companies advertise topical finasteride with limited disclosures of side effects.

According to the FDA, they have not received official approval, and no comprehensive safety data has been submitted for them.

FDA warning on topical finasteride: The FDA issued a warning about the topical form of finasteride (generic Propecia), often ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Commissioner Marty Makary said he has no plans to change current policy to restrict access to the abortion pill mifepristone, ...

A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left ...

Sen. Josh Hawley said it is "extremely disappointing" that FDA Commissioner Dr. Marty Makary has "no plans" for abortion ...

Eli Lilly (NYSE:LLY) has filed lawsuits against four telehealth platforms that the pharma giant alleges are selling ...

Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) ...